TMS Co., Ltd. (JP:4891) has released an update.
TMS Co., Ltd., a clinical-stage biopharmaceutical company, is making strides with its promising lead program, TMS-007, aimed at treating acute ischemic stroke, a field that hasn’t seen a new drug in decades. The company’s CEO, Takuro Wakabayashi, highlighted this potential breakthrough and discussed an emerging pipeline addressing hypertension, kidney injury, and spinal cord injury during an interview on Biotech TV.
For further insights into JP:4891 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
